Nuo Therapeutics Inc
OTC:AURX
Nuo Therapeutics Inc
Goodwill
Nuo Therapeutics Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nuo Therapeutics Inc
OTC:AURX
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gartner Inc
NYSE:IT
|
Goodwill
$2.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
14%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Goodwill
$16.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
37%
|
|
|
Ionis Pharmaceuticals Inc
NASDAQ:IONS
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cytokinetics Inc
NASDAQ:CYTK
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nuo Therapeutics Inc
Glance View
Nuo Therapeutics, Inc. is a biomedical company. The company is headquartered in Houston, Texas and currently employs 7 full-time employees. The company went IPO on 2017-01-19. The firm's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds. The firm commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company’s Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. The firm is marketing its products primarily within the United States. Nuo Therapeutics' s Aurix System produces a platelet rich plasma (PRP), gel at the point of care using the patient’s own platelets and plasma. The Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
